Immune Checkpoint Inhibitors: Special Topics | China In-Depth | China | 2022

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as an effective treatment option against cancer. China has the most crowded immune checkpoint inhibitors market globally with 12 approved therapies and many more in development, encouraged by the ongoing reforms in China’s regulatory and access and reimbursement landscape. The growing incorporation of these agents in the treatment paradigm for many cancers has led to significant growth of China’s immune checkpoint inhibitor market over the last few years. Moreover, the incorporation of four domestic immune checkpoint inhibitors—sintilimab (Innovent Bio’s Tyvyt), camrelizumab (Hengrui Medicine’s AiRuiKa), tislelizumab (BeiGene’s Baize’an), and toripalimab (Junshi Bio’s TuoYi)—into China’s National Reimbursement Drug List (NRDL) has greatly improved patient access. Based on the rising use, rich pipeline, and improving access and reimbursement of immune checkpoint inhibitors in the country, we anticipate that China will become a market leader in the immune checkpoint inhibitors space during the forecast period.

QUESTIONS ANSWERED

• Which are the key immune checkpoint inhibitors approved and in development in China?
• Which will be the most commercially relevant immune checkpoint inhibitors in China and why?
• What are interviewed experts’ opinions about the role of immune checkpoint inhibitors? What are the key factors influencing their treatment decisions?
• What are the market access considerations for key immune checkpoint inhibitors in China?
• How will the market evolve over the next ten years (2021 to 2031)?

PRODUCT DESCRIPTION

Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the immune checkpoint inhibitor landscape in select oncology indications.

RELEASE DATE

April 2021

GEOGRAPHY

China

PRIMARY RESEARCH

Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 oncologists

INDICATION COVERED

• Non-small-cell lung cancer (NSCLC)
• Hepatocellular carcinoma (HCC)
• Gastroesophageal cancer (GEC)
• Breast cancer

FORECAST

10-year, annualized, drug-level sales of key immune checkpoint inhibitors through 2031, based on primary and secondary market research to formulate bottom-up assumptions

EMERGING THERAPIES

Phase III/PR: 14 drugs